European Journal of Cancer
Volume 42, Issue 1 , Pages 17-23 , January 2006

Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy

  • S.K. Chan

      Affiliations

    • Cancer Biology Laboratory, Research School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
    • Kent Oncology Center, Maidstone Hospital, Maidstone, Kent ME16 9QQ, United Kingdom
    • ,
  • W.J. Gullick

      Affiliations

    • Cancer Biology Laboratory, Research School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom
    • Corresponding Author InformationCorresponding author: Tel.: +44 1227 823014; fax: +44 1227 827221.
    • ,
  • M.E. Hill

      Affiliations

    • Kent Oncology Center, Maidstone Hospital, Maidstone, Kent ME16 9QQ, United Kingdom

Received 29 June 2005 ,Revised 6 July 2005 ,Accepted 7 July 2005.

References 

  1. Toms J. CancerStats monograph. London: Cancer Research UK; 2004.
  2. http://www-dep.iarc.fr/HMP/CAMON.htm.
  3. GLOBOCAN. Cancer incidence, mortality and prevalence worldwide (2000 estimates); 2001.
  4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98
  5. D’Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–2936
  6. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548–5557
  7. Casalini P, Iorio MV, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200(3):343–350
  8. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res. 2003;284(1):2–13
  9. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31–53
  10. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl. 4):S9–S15
  11. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist. 2002;7(Suppl. 4):31–39
  12. Salomon D, Gullick W. The erbB family of receptors and their ligands: multiple targets for therapy. Signal. 2001;2(3):4–11
  13. Weinstein IB. Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science. 2002;297(5578):63–64
  14. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53(Suppl. 10):2379–2385
  15. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998;4(1):241–249
  16. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62(20):5749–5754
  17. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19(13):3267–3279
  18. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial) [corrected]. J Clin Oncol. 2003;21(12):2237–2246
  19. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290(16):2149–2158
  20. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A national cancer institute of canada clinical trials group (NCIC CTG) trial. In: ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 2004; 22(14S); 7022 [July 15 Suppl.].
  21. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol. 2004;22(16):3238–3247
  22. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1. J Clin Oncol. 2004;22(5):777–784
  23. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol. 2004;22(5):785–794
  24. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). In: ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 2004; 22(14S): 7010 [July 15 Suppl.].
  25. Herbst RS, Prager D, Hermann R, et al. TRIBUTE – A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). In: ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 2004; 22(14S): 7011 [July 15 Suppl.].
  26. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139
  27. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500
  28. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101(36):13306–13311
  29. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23(11):2493–2501
  30. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23(4):857–865
  31. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339–346
  32. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol. 2005;23(11):2513–2520
  33. Huang SF, Liu HP, Li LH, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res. 2004;10(24):8195–8203
  34. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004;64(24):8919–8923
  35. Qin BM, Chen X, Zhu JD, et al. Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Res. 2005;15(3):212–217
  36. Sasaki H, Endo K, Konishi A, et al. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 2005;11(8):2924–2929
  37. Soung YH, Lee JW, Kim SY, et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 2005;
  38. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2005;11(6):2106–2110
  39. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643–655
  40. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol. 2005;
  41. WHO. Male smoking trends 1960–2000.
  42. WHO. Female smoking trends 1960–2000.
  43. Lynch TJ, Bell D, Haber D, et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. In: 2005 ASCO annual meeting abstract No. 7006 and associated oral presentation; 2005.
  44. Collins VP. Gene amplification in human gliomas. Glia. 1995;15(3):289–296
  45. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163–1167
  46. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73
  47. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–792
  48. Toyooka S, Kiura K, Mitsudomi T. EGFR mutation and response of lung cancer to gefitinib. N Engl J Med. 2005;352(20):2136;author reply 2136
  49. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401
  50. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–526
  51. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65(5):1642–1646
  52. Han SW, Jeong S, Choi IS, et al. EGFR and K-ras mutations as determinants of gefitinib sensitivity in non-small-cell lung cancer (NSCLC). In: 2005 ASCO annual meeting abstract no. 7078; 2005.
  53. Lee JW, Soung YH, Kim SY, et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11(8):2879–2882
  54. Udagawa K, Nagai Y, Akaishi T, et al. Clinical evaluation of a rapid and sensitive detection system for epidermal growth factor receptor (EGFR) mutations named PNA-LNA PCR clamp. In: 2005 ASCO annual meeting abstract no. 3072; 2005.
  55. Kawada I, Soejima K, Watanabe H, et al. Quick screening of EGFR mutation using restriction fragment length polymorphism. In: 2005 ASCO annual meeting abstract no. 7071; 2005.
  56. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005;23(13):2946–2954
  57. Lee KH, Han SW, Jeong S, et al. EGFR mutation and response to chemotherapy in non-small-cell lung cancer (NSCLC) patients. In: 2005 ASCO annual meeting abstract no. 7084; 2005.
  58. Sledge GWJ. In: 2005 ASCO annual meeting. session: advances in monoclonal antibody therapy for breast cancer (scientific symposium); 2005.
  59. Soung YH, et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer. 2005;September:

PII: S0959-8049(05)00946-9

doi: 10.1016/j.ejca.2005.07.031

European Journal of Cancer
Volume 42, Issue 1 , Pages 17-23 , January 2006

Article Tools

* Image Usage & Resolution